Skip to content
Screener

Similar metrics at other companies

HWK
HWKNPharmaceutical — Revenue
$6.97M+25.3%
Zoetis logo
ZTSOther pharmaceutical — Revenue
$168M-4.0%
AMP
AMPHFinished Pharmaceutical Products — Revenue
$183.9M+5.4%
Cardinal Health logo
CAHPharmaceutical and Specialty Solutions — Revenue
$56.11B+11.3%
Zoetis logo
ZTSOther Non Pharmaceuticals — Revenue
$70M+2.9%
Gyre Therapeutics, Inc. logo
GYREGyre Pharmaceuticals — Revenue
$29.1M+8.7%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Revenue:
United States$243,116$156,506$457,184$294,102
United Kingdom484291682480
Total revenue$243,600$156,797$457,866$294,582

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's business segments — revenue?
Kiniksa Pharmaceuticals International, plc (KNSA) reported business segments — revenue of $243.6M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's business segments — revenue changed year-over-year?
Kiniksa Pharmaceuticals International, plc's business segments — revenue increased by 55.4% year-over-year, from $156.8M to $243.6M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's business segments — revenue?
Over 2 years (2023 to 2025), Kiniksa Pharmaceuticals International, plc's business segments — revenue has grown at a 58.3% compound annual growth rate (CAGR), from $270.26M to $677.56M.
What does business segments — revenue mean?
The total gross income generated from the sale of pharmaceutical products and services within the segment. It serves as the primary indicator of market adoption and commercial success for the company's therapeutic portfolio.

Ask your AI about Kiniksa Pharmaceuticals International, plc's business segments — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude